282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. (23rd October 2018) - Fasching, P A; Decker, T; Guderian, G; Heim, J; Jackisch, C; Lueck, H-J; Lüftner, D; Marmé, F; Reimer, T; Woeckel, A